Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model

Exp Hematol. 2007 Aug;35(8):1201-8. doi: 10.1016/j.exphem.2007.05.007.


Objective: To evaluate the potential of Hematide, a PEGylated, synthetic peptide-based erythropoiesis-stimulating agent that is in clinical development for the treatment of anemia associated with chronic kidney disease and cancer, to correct antierythropoietin antibody-associated pure red cell aplasia (PRCA).

Materials and methods: The binding of anti-Hematide antibodies (mouse, rabbit, and monkey) to recombinant human erythropoietin (rHuEPO) and of anti-rHuEPO antibodies (mouse, goat, rat, and human) to Hematide were evaluated. An anti-EPO antibody-mediated anemia rat model was developed by subcutaneously administering rHuEPO to rats three times weekly for 4 weeks. Sixty percent of the animals developed PRCA as characterized by severe anemia, reduced reticulocytes, anti-EPO antibodies, and limited bone marrow erythroid precursors. The effect of Hematide administration on the PRCA rats was evaluated.

Results: Antibodies to EPO do not cross react with Hematide and, conversely, antibodies to Hematide do not cross react with EPO. Hematide corrected antibody-induced anemia in a rat PRCA model.

Conclusions: The data support the potential of Hematide to correct anti-EPO antibody-associated PRCA in humans. In addition, the data suggest a negligible risk for development of anti-EPO antibody-induced PRCA secondary to Hematide administration.

MeSH terms

  • Anemia / drug therapy*
  • Anemia / etiology
  • Animals
  • Antibodies
  • Bone Marrow / pathology
  • Bone Marrow / physiopathology
  • Colony-Forming Units Assay
  • Disease Models, Animal
  • Erythropoietin / immunology*
  • Erythropoietin / pharmacology
  • Erythropoietin / therapeutic use
  • Humans
  • Peptides / immunology
  • Peptides / pharmacology*
  • Polyethylene Glycols / pharmacology*
  • Rabbits
  • Rats
  • Red-Cell Aplasia, Pure / drug therapy*
  • Red-Cell Aplasia, Pure / pathology


  • Antibodies
  • Peptides
  • hematide
  • Erythropoietin
  • Polyethylene Glycols